Cyclacel Pharmaceuticals Files 8-K: Material Agreement & Exhibits
Ticker: BGMSP · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1130166
Sentiment: neutral
Topics: material-agreement, filing, exhibits
Related Tickers: CYCC
TL;DR
Cyclacel filed an 8-K for a material agreement and exhibits on Feb 20, 2025. Details TBD.
AI Summary
On February 20, 2025, Cyclacel Pharmaceuticals, Inc. entered into a material definitive agreement. The company also filed financial statements and exhibits as part of this 8-K report. The filing does not specify the nature of the agreement or the financial details.
Why It Matters
This filing indicates a significant event for Cyclacel Pharmaceuticals, Inc., potentially involving a new contract or financial update that could impact its operations and future prospects.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent a significant development, but the lack of specific details necessitates a medium risk assessment.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- February 20, 2025 (date) — Date of earliest event reported
- 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 (address) — Business and Mail Address
FAQ
What is the nature of the material definitive agreement entered into by Cyclacel Pharmaceuticals, Inc. on February 20, 2025?
The filing does not specify the nature of the material definitive agreement.
What specific financial statements and exhibits were filed with this 8-K report?
The filing indicates that financial statements and exhibits were included, but does not list their specific contents.
What is the Commission File Number for Cyclacel Pharmaceuticals, Inc.?
The Commission File Number for Cyclacel Pharmaceuticals, Inc. is 000-50626.
What is the IRS Employer Identification Number for Cyclacel Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Cyclacel Pharmaceuticals, Inc. is 91-1707622.
What was the former name of Cyclacel Pharmaceuticals, Inc. and when did the name change occur?
The former name was XCYTE THERAPIES INC, and the date of the name change was December 18, 2000.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).